Federal health advisers on Tuesday endorsed a lower-cost version of Johnson & Johnson's blockbuster Remicade, a pricey biotech medicine used to treat a number of inflammatory diseases.
By Matthew Perrone Associated Press, San Jose Mercury News: Business
Tue, 02/09/2016 - 5:41pm
Federal health advisers on Tuesday endorsed a lower-cost version of Johnson & Johnson's blockbuster Remicade, a pricey biotech medicine used to treat a number of inflammatory diseases.